Seer Launches First-of-its-kind Proteogenomics Workflow to Link Genetic Changes with Protein Variants with Proteograph™ Analysis Suite 2.0
August 03 2022 - 9:00AM
Seer Inc. (NASDAQ: SEER), a life sciences company commercializing a
disruptive new platform for proteomics, today announced a new
Proteogenomics Workflow that integrates deep, unbiased proteomics
with genomics, powered by the Proteograph Analysis Suite 2.0,
Seer’s software suite for data analysis and results visualization.
The release of the workflow marks another milestone on Seer’s
journey to enabling accurate, high-resolution, peptide-level
proteogenomics at scale and follows the formation of its
Proteogenomics Consortium in the first half of this year.
Understanding the connection between genes and proteins at the
peptide sequence-level is necessary to understand human health and
disease, drive biomarker discovery and enable the development of
novel therapeutics. Proteins dictate the body's physiological
response to disease and are in turn influenced by disease state. A
single gene typically gives rise to multiple protein variants, such
as splice variants, which can have distinct physiological roles and
impact on biology. Each protein variant gives rise to a different
profile of peptides, which the Proteograph Product Suite can
identify and quantify, resolving known and novel protein variants
at the peptide level. Current affinity-based approaches survey
changes for a set of predefined protein targets, missing
potentially important variants of these predefined proteins and
delivering an incomplete view of the relationship between the
genome and the proteome.
Seer’s Proteograph Analysis Suite 2.0 is a key component of the
Proteograph™ Product Suite, which provides unbiased, deep,
rapid proteomics at scale that is peptide-centric, and enables
high-resolution identification of protein variants. This next
version of the Proteograph Analysis Suite incorporates a
Proteogenomic Workflow that maps proteomic, peptide-level data to
genomic data to identify sample-specific variant peptides not
captured in canonical reference databases. The workflow summarizes
results in interactive tables and plots, enables the visualization
of identified peptides’ relationship to gene structure, protein
domain information, and functional regions; and creates browsable
peptide data maps at the amino acid level. The Proteograph Analysis
Suite’s intuitive visualizations make it faster and easier to
discover protein targets for a wide range of applications.
“We’re thrilled to deliver PAS 2.0, this new Proteogenomic
Workflow, and our other exciting future improvements that make it
easier for different customer groups to adopt deep, unbiased
proteogenomics at scale,” said Serafim Batzoglou, Ph.D., Senior
Vice President, Data at Seer. “Making proteomic analysis tools more
accessible for researchers is one of Seer’s main priorities, and
today’s announcement is another step towards achieving that
goal.”
The launch of the Proteogenomic Workflow furthers Seer’s
commitment to enabling broader access to proteogenomic tools. In
January, Seer formed the Proteogenomics Consortium with Discovery
Life Sciences, a global leader in biomarker development and
biospecimen solutions utilizing proteomic, genomic, cell, and
immunohistochemistry technologies, and SCIEX, a global leader in
life science analytical technologies. The collaboration is intended
to enable genomics customers to add deep, unbiased proteomics data
more easily to their studies, allowing the discovery of new protein
variants and novel biomarkers that could lead to therapeutic
breakthroughs.
“At Discovery Life Sciences, we are excited by the features
we’ve seen demonstrated by this new tool and are eager to
incorporate the new features in the Proteograph Analysis Suite 2.0
into our services pipeline at our new facility outside Boston,”
said Michael Pisano, Ph.D., Executive Vice President, Proteomics at
Discovery Life Sciences.
The Proteograph Analysis Suite v2.0 rollout is underway, with
Seer customers having immediate access to the new workflow and
features in the software. For more information, visit
https://seer.bio/PAS.
About Seer
Seer is a life sciences company developing transformative
products that open a new gateway to the proteome. Seer’s
Proteograph™ Product Suite is an integrated solution that includes
proprietary engineered nanoparticles, consumables, automation
instrumentation and software to perform deep, unbiased proteomic
analysis at scale in a matter of hours. Seer designed the
Proteograph workflow to be efficient and easy to use, leveraging
widely adopted laboratory instrumentation to provide a
decentralized solution that can be incorporated by nearly any lab.
Seer’s Proteograph Product Suite is for research use only and is
not intended for diagnostic procedures. For more information,
please visit www.seer.bio.
Forward-Looking Statements
This press release contains “forward-looking
statements” within the meaning of the Private Securities Litigation
Reform Act of 1995, as amended. Such forward-looking statements are
based on Seer’s beliefs and assumptions and on information
currently available to it on the date of this press release.
Forward-looking statements may involve known and unknown risks,
uncertainties and other factors that may cause Seer’s actual
results, performance, or achievements to be materially different
from those expressed or implied by the forward-looking statements.
These statements include but are not limited to statements
regarding Seer’s Proteograph Analysis Suite’s functionality and
ability to enable accurate, high-resolution, peptide-level
proteogenomics at scale and Seer’s collaboration with Discovery
Life Sciences and SCIEX. These and other risks are described more
fully in Seer’s filings with the Securities and Exchange Commission
(“SEC”) and other documents that Seer subsequently files with the
SEC from time to time. Except to the extent required by law, Seer
undertakes no obligation to update such statements to reflect
events that occur or circumstances that exist after the date on
which they were made.
Investor Contact Carrie Mendivil
investor@seer.bio
Media Contact Karen Possemato
pr@seer.bio
Seer (NASDAQ:SEER)
Historical Stock Chart
From Jun 2024 to Jul 2024
Seer (NASDAQ:SEER)
Historical Stock Chart
From Jul 2023 to Jul 2024